CAS NO: | 143113-45-5 |
包装: | 500μg |
市场价: | 3308元 |
Cas No. | 143113-45-5 |
化学名 | (2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S,15Z,17S,18Z,20S,21Z,23S,24Z,26S,27Z,29S,30Z,32S,33Z,35S,36Z,38S,39Z,41S)-17-((1H-imidazol-5-yl)methyl)-2-((1H-indol-3-yl)methyl)-38-(4-aminobutyl)-23-benzyl-5,8-di((S)-sec-butyl)-35-(2-carboxyethyl)-11-(carboxymethyl)-4,7,10 |
Canonical SMILES | CC[C@]([C@@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/C)([H])CC(C)C)([H])CCSC)([H])CC(O)=O)([H])CCCCN)([H] |
分子式 | C96H140N20O25S |
分子量 | 2006.32 |
溶解度 | Soluble to 0.50 mg/ml in sodium bicarbonate (0.03M) |
储存条件 | Desiccate at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | BQ-3020 is a linear endothelin (ET) analog that is highly selective for ETB receptors. It displaces [125I] ET-1 binding to ETB receptors in porcine cerebellar membranes with an IC50 value of 0.2 nM [1]. ET-1, a 21-amino acid peptide, is one of known isoforms of endothelin (ET-1, ET-2, ET-3), it has strong vasoconstrictor and mitogenic activity. ETB receptor is one of endothelin receptors (i.e. ETA and ETB). ETB receptor has nearly the same affinity for all endothelin isoforms [2]. BQ-3020 displaced [125I] ET-1 binding to ETB receptors in porcine cerebellar membranes at a concentration 4,700 times lower than that to ETA receptors (selective to ET-1) on aortic vascular smooth muscle cells (IC50: 940 nM) [1]. In eight healthy men aged from 20-28 years, the local response of Sarafotoxin S6c (SFTX6c) (5 pmol/min) or BQ-3020 (50 pmol/min) to intra-arterial or intravenous infusion was assessed. Comparing these studies, there was no significant difference between baseline measurements. All the effects were just in the infused arm. Following intra-arterial infusion, both SFTX6c and BQ-3020 produced vasoconstriction indicated by the reduction in forearm blood flow (-25±7% and -27±7%, respectively). Following intravenous infusion, both SFTX6c and BQ-3020 produced a vein diameter reduction (-30±8% and -16±7%, respectively) [3]. References: |